Drug intelligence / Profile preview

DF19001

Development stage: Phase 1
Lead developer: RAPHAS
Modality: Vaccines & Immunotherapeutics
Administration: Transdermal

Overview

DF19001 is a transdermal absorption immunotherapy agent developed for the treatment of allergic rhinitis, particularly in patients sensitized to house dust mite (HDM, Dermatophagoides farinae). It addresses limitations of conventional immunotherapy drugs through a novel transdermal delivery method, aiming to induce immune tolerance. The exact mechanism, such as specific allergen targeting or immune modulation pathway, is not detailed in available clinical data, but it is under investigation in early clinical studies by RAPHAS Co Ltd.[1][3][11]

Other names: house dust mite extract, dermatophagoides farinae-RAPHAS-allergic rhinitisHouse Dust Mite Extract microneedle patch

Targets

House dust mite allergen antigens

Beyond the preview

Go deeper on DF19001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DF19001.

Explore the full profile